Drug Profile
Atoltivimab/maftivimab/odesivimab - Regeneron Pharmaceuticals
Alternative Names: Atoltivimab/3471/3479 - Regeneron Pharmaceuticals; Atoltivimab/maftivimab/odesivimab-ebgn; Ebola virus antibody - Regeneron Pharmaceuticals; Inmazeb; REGN 3470/3471/3479; REGN 3470/3471/Maftivimab - Regeneron Pharmaceuticals; REGN 3470/odesivimab/3479 - Regeneron Pharmaceuticals; REGN-EB3; REGN3470-3471-3479Latest Information Update: 02 Nov 2022
Price :
$50
*
At a glance
- Originator Regeneron Pharmaceuticals
- Developer National Institute of Allergy and Infectious Diseases; Regeneron Pharmaceuticals
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action Antibody-dependent cell cytotoxicity; Phagocyte stimulants; Virus internalisation inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Ebola virus infections
Most Recent Events
- 15 Mar 2022 Launched for Ebola virus infections (In adolescents, In children, In the elderly, In infants, In neonates, In adults) in USA (IV)
- 14 Oct 2020 Registered for Ebola virus infections (In adolescents, In adults, In children, In infants, In neonates, In the elderly) in USA (IV) - First global approval
- 14 Oct 2020 Atoltivimab/maftivimab/odesivimab is available for Ebola virus infections for compassionate use in Congo, under the Monitored Emergency Use of Unregistered and Investigational Interventions(MEURI) protocol